Our results suggested that not only the direct effects of Amatuximab but also the environmental changes induced by Amatuximab could control the stemness of pancreatic cancer cells expressing high mesothelin, and these resulted in an improvement of sensitivity for gemcitabine in mesothelin-expressing pancreatic cancer cells. This evidence concerns the gene MSLN and familial pancreatic carcinoma.